Mylan Inc  

(Public, NASDAQ:MYL)   Watch this stock  
Find more results for Mylan Inc
48.08
-0.22 (-0.46%)
Aug 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 47.90 - 48.63
52 week 34.46 - 57.52
Open 48.48
Vol / Avg. 3.03M/5.19M
Mkt cap 18.07B
P/E 32.73
Div/yield     -
EPS 1.47
Shares 374.05M
Beta 1.23
Inst. own 92%
Oct 29, 2014
Q3 2014 Mylan Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Sep 18, 2014
Mylan Inc Investor Day Add to calendar
Aug 7, 2014
Q2 2014 Mylan Inc Earnings Call
Aug 7, 2014
Q2 2014 Mylan Inc. Earnings Release
Jul 14, 2014
Abbott Laboratories M&A Call - Mylan Inc Acquisition of Generics Pharmaceuticals Business - Webcast
Jul 14, 2014
Mylan Inc To Acquire Abbott's Non-U.S. Developed Markets Specialty And Branded Generics Business In An All-Stock Transaction M&A Call
Jun 10, 2014
Mylan Inc. at Goldman Sachs Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 6.89% 9.07%
Operating margin 12.31% 16.80%
EBITD margin - 26.89%
Return on average assets - 4.61%
Return on average equity - 19.86%
Employees 20,000 -
CDP Score - -

Address

1000 MYLAN BOULEVARD
CANONSBURG, PA 15317
United States - Map
+1-724-5141800 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Mylan Inc. (Mylan) is a fully integrated global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. Mylan has two segments:Generics and Specialty. Its generic pharmaceutical business is conducted primarily in the United States and Canada (collectively, North America); Europe, the Middle East, and Africa (collectively, EMEA); and India, Australia, Japan and New Zealand (collectively, Asia Pacific). Its API business is conducted through Mylan Laboratories Limited (Mylan India), which is included within the Asia Pacific region in its Generics Segment. The Company's pharmaceutical business is conducted by Mylan Specialty L.P. (Mylan Specialty). Mylan provides products to customers in approximately 140 countries and territories. In December 2013, In December 2013, the Company announced that it has completed the acquisition of the Agila injectables businesses from Strides Arcolab Ltd.

Officers and directors

Robert J. Coury Executive Chairman of the Board
Age: 53
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Rajiv Malik President, Director
Age: 52
Bio & Compensation  - Reuters
Heather M. Bresch Chief Executive Officer, Director
Age: 44
Bio & Compensation  - Reuters
Rodney L. Piatt CPA Vice Chairman of the Board, Lead Independent Director
Age: 61
Bio & Compensation  - Reuters
John D. Sheehan CPA Executive Vice President, Chief Financial Officer, Principal Financial officer
Age: 53
Bio & Compensation  - Reuters
Rakesh Bamzai President - India Commercial and Emerging Markets
Bio & Compensation  - Reuters
Anthony Mauro President, North America
Age: 41
Bio & Compensation  - Reuters
Wendy Cameron Independent Director
Age: 54
Bio & Compensation  - Reuters
Robert J. Cindrich Independent Director
Age: 70
Bio & Compensation  - Reuters
Neil F. Dimick CPA Independent Director
Age: 64
Bio & Compensation  - Reuters